Janus kinase inhibitors: An innovative treatment for alopecia areata

Alopecia areata (AA) is a relatively common disease, but no satisfactory treatment has yet been developed. Recently, research progress has been made in the pathogenesis of AA, revealing that autoreactive cytotoxic T cells are important and that the Janus kinase (JAK) pathway is involved. Therefore,...

Full description

Saved in:
Bibliographic Details
Published inJournal of dermatology Vol. 46; no. 8; pp. 724 - 730
Main Authors Park, Hyunsun, Yu, Da‐Ae, Kwon, Ohsang
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.08.2019
Subjects
Alopecia
alopecia areata
Baldness
baricitinib
Clinical trials
Cytotoxicity
Hair loss
Inhibitor drugs
Janus kinase
Janus kinase inhibitors
Lymphocytes T
ruxolitinib
tofacitinib
baricitinib
ruxolitinib
alopecia areata
Janus kinase inhibitors
tofacitinib
Online AccessGet full text

Cover

More Information
Summary:Alopecia areata (AA) is a relatively common disease, but no satisfactory treatment has yet been developed. Recently, research progress has been made in the pathogenesis of AA, revealing that autoreactive cytotoxic T cells are important and that the Janus kinase (JAK) pathway is involved. Therefore, the potential of JAK inhibitors as therapeutic agents for AA is attracting attention. Several single‐arm clinical trials and retrospective studies demonstrated that oral JAK inhibitors are effective and tolerable treatments for moderate to severe AA. Although JAK inhibitors are emerging as an innovative treatment for AA, further placebo‐controlled clinical trials are required to confirm their efficacy and long‐term safety.
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.14986